


Journal Pre-proof

Exploring the impact of the GJA4 rs618675 variant on cardiovascular prevention

Maria Isabel Mendonça Roberto Palma dos Reis Débora Sá
Francisco Sousa Eva Henriques Sofia Borges Sónia Freitas Mariana
Rodrigues Graça Guerra António Drumond Ana Célia Sousa



PII: S0870-2551(26)00207-6

DOI: <https://doi.org/doi:10.1016/j.repc.2026.03.013>

Reference: REPC 2585

To appear in: *Revista Portuguesa de Cardiologia*

Received Date: 10 April 2025

Accepted Date: 30 March 2026

Please cite this article as: Mendonça MI, Reis RPd, Sá D, Sousa F, Henriques E, Borges S, Freitas S, Rodrigues M, Guerra G, Drumond A, Sousa AC, Exploring the impact of the GJA4 rs618675 variant on cardiovascular prevention, *Revista Portuguesa de Cardiologia* (2026), doi: <https://doi.org/10.1016/j.repc.2026.03.013>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2026 Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia.

Exploring the impact of the GJA4 rs618675 variant on cardiovascular prevention

Explorando o impacto da variante GJA4 rs618675 na prevenção cardiovascular

GJA4 and Cardiovascular Prevention

GJA4 e Prevenção Cardiovascular

Maria Isabel Mendonça^{1*}, Roberto Palma dos Reis², Débora Sá^{1,3}, Francisco Sousa^{1,3}, Eva Henriques¹, Sofia Borges¹, Sónia Freitas¹, Mariana Rodrigues¹, Graça Guerra¹, António Drumond³, Ana Célia Sousa^{1,4}

¹Centro de Investigação Dr^a Maria Isabel Mendonça, Hospital Dr. Nélío Mendonça, SESARAM EPERAM, Funchal, Portugal

²NOVA Medical School, Faculdade de Ciências Médicas, Lisboa, Portugal


³Serviço de Cardiologia, Hospital Dr. Nélío Mendonça, SESARAM EPERAM, Funchal, Portugal

⁴Faculdade de Medicina da Universidade da Madeira (UMa), Campus Universitário da Penteada, Funchal, Portugal

*Corresponding author: m.isabel.mendonca@hotmail.com (Maria Isabel Mendonça)

Word count: 5325

Graphical abstract



ABSTRACT

Introduction and objectives: The gap junction alpha-4 (*GJA4*) gene, which encodes connexin37, regulates endothelial function and influences inflammation, platelet adhesion, and thrombus formation in vascular endothelial cells, which may favour atherosclerosis and cardiovascular (CV) events. The main objective is to assess whether the *GJA4* rs618675 T>C variant is a risk factor for the onset of CV events in an asymptomatic Portuguese population.

Methods: 1421 individuals without CV disease (52.2 ± 8.3 years, 73.6% male) were followed up during a mean of 7.3 ± 6.0 years, and CV events were recorded. *GJA4* rs618675 T>C was genotyped by real-time PCR (TaqMan), and four genetic models were created. We analysed traditional, biochemical and clinical risk factors. We performed bivariate analysis and adjusted logistic regression with respective OR. Kaplan-Meier estimated event-free survival and Cox regression, adjusted for confounding, evaluated the association between four genetic models and CV events (HR).

Results: Wild TT genotype, TC, and CC were 50.6%, 39.2%, and 10.1% in the CV events group and 66.2%, 30.4% and 3.4% in the non-events group ($p=0.001$). After logistic regression, the codominant model (CCvsTT and CTvsTT) showed an OR of 3.9 ($p=0.002$). Kaplan-Meier showed 87.6% event-free time for TT and 64.8% for CC ($p=0.005$). Adjusted Cox regression identified the codominant model as the best predictor (HR=2.8; $p=0.008$), together with male gender (HR=2.1; $p=0.020$), age (HR=1.1; $p=0.001$), hypertension (HR=1.9; $p=0.014$), smoking (HR=1.9; $p=0.010$), and leucocytosis (HR=1.2; $p=0.003$).

Conclusion: We have demonstrated that the CC variant of *GJA4* is significantly associated with CV events. Further investigations into this biomarker may improve CV risk prediction, leading to better primary prevention.

Resumo:

Introdução e objectivos: O gene *GJA4* codifica a proteína das junções comunicantes alfa-4 (Conexina37) e regula a função endotelial, influenciando a inflamação, adesão plaquetária e formação de trombos nas células endoteliais vasculares favorecendo a ocorrência de eventos cardiovasculares (CV). Avaliar a variante *GJA4* rs618675 T>C como fator de risco para o aparecimento de eventos CV numa população Portuguesa assintomática.

Métodos: 1421 indivíduos sem doença cardiovascular ($52,2 \pm 8,3$ anos, 73,6% homens) foram seguidos durante $7,3 \pm 6,0$ anos e os eventos CV registados. *GJA4* rs618675 T>C foi genotipado por PCR em tempo real (TaqMan) em quatro modelos genéticos. Analisámos os fatores de risco tradicionais, bioquímicos e clínicos. Efectuámos análise bivariada e regressão logística ajustada. Kaplan-Meier estimou o tempo sem eventos, a regressão de Cox avaliou a associação entre 4 modelos genéticos e os eventos CV.

Resultados: O genótipo selvagem TT, TC e o mutante CC apresentaram, respetivamente, 50,6%, 39,2% e 10,1% no grupo com eventos e 66,2%, 30,4% e 3,4% no grupo sem eventos ($p=0,001$). Após regressão logística, o modelo codominante (CCvsTT e CTvsTT) apresentou um OR de 3,9 ($p = 0,002$). Kaplan-Meier mostrou 87,6% melhor probabilidade de ausência de eventos para TT e 64,8% para CC ($p=0,005$). A regressão de Cox mostrou que o melhor modelo foi o codominante (HR=2,8; $p=0,008$), juntamente com género masculino (HR=2,1; $p=0,020$), idade (HR=1,1; $p=0,001$), hipertensão (HR=1,9; $p=0,014$), tabagismo (HR=1,9; $p=0,010$) e leucocitose (HR=1,2; $p=0,003$).

Conclusão: A variante CC do gene *GJA4* está significativamente associada a eventos cardiovasculares. Investigação adicional sobre este biomarcador pode melhorar a previsão do risco CV, permitindo uma melhor prevenção primária.

Keywords: *GJA4* gene; Connexins; Atherosclerosis; Cardiovascular events.

Palavras-Passe: Gene *GJA4*; Conexinas; Aterosclerose; Eventos cardiovasculares.

1- INTRODUÇÃO

The Gap junction alpha-4 (*GJA4*) gene, which encodes connexin37 (Cx37), belongs to the connexin family. Full-length connexins (Cxs) oligomerise and create channel structures that connect the cytosol of adjacent cells (gap junctions) or the cytosol with the extracellular zone (hemichannels).¹ These channels allow the transfer of ions and small molecules, facilitating rapid, efficient communication between cells.² Cxs proteins play essential roles in vascular cells, ranging from electrical coupling to vascular remodelling, angiogenesis, and vascular permeability.³ Cx37 is a member of the connexin family of proteins and is expressed in endothelial cells, macrophages, and platelets, protecting against atherosclerosis by controlling monocyte adhesion and having a growth-suppressive effect on endothelial cells. Cx37 is essential for endothelial health and helps regulate the inflammatory processes involved in atherosclerosis. Additionally, it maintains the stability of atherosclerotic plaques, preventing their vulnerability.⁴ Platelets also express *GJA4* and Cx37, which are required to form a stable and effective clot when a vascular injury occurs.⁵ Inhibition of Cx37 function in platelets is controversial, but studies show that it reduces platelet aggregation and thrombus formation in mice, highlighting its critical role in these processes.⁶⁻⁷ Some *GJA4* polymorphisms that alter cell adhesion and monocyte function can influence the risk of conditions such as atherosclerosis, coronary artery disease, and myocardial infarction. The *GJA4* rs618675 T>C single-nucleotide polymorphism (SNP) has been previously identified in the Framingham Offspring Cohort as being significantly associated with cardiovascular (CV) events (HR=1.73; 95% CI 1.01–2.97; p=0.045).⁸⁻⁹ Although this variant lies in a non-coding intronic region and does not alter the Cx37 protein sequence, its association with CV outcomes may reflect linkage disequilibrium (LD) with a nearby functional missense variant or another regulatory mechanism affecting *GJA4* expression and transcription. Given the biological plausibility of these mechanisms and the robust epidemiological association observed in the Framingham Offspring Study, we aimed to replicate and validate the rs618675 variant in our cohort to investigate further its potential contribution to cardiovascular risk in asymptomatic individuals from Madeira Island.

2- OBJECTIVE

This work aims to investigate whether the *GJA4* rs618675 is a risk factor for the development of CV events in an asymptomatic Portuguese population without apparent CV disease.

3- METHODS

3.1 - Study Population and Data Collection

A total of 1421 individuals without apparent CVD, randomly selected from the electoral rolls of the Madeira Archipelago, were included in this study. They were admitted and prospectively enrolled on the Research Centre dataset, SESARAM EPERAM, during a mean follow-up of 7.3 ± 6.0 years. Participants were enrolled between 2000 and 2019. Inclusion/exclusion criteria were used, and asymptomatic individuals aged 35–65 years, without established cardiovascular disease were enrolled. A specialist cardiologist performed a complete clinical examination, including an electrocardiogram, and, when necessary, stress testing or echocardiography, confirming the absence of clinical or functional evidence of cardiovascular disease. Each participant was questioned about their demographic and traditional risk factors like age, gender, smoking and alcohol habits, diabetes mellitus, dyslipidemia, physical inactivity and arterial hypertension, as previously defined.¹⁰ All laboratory analyses (total, LDL, HDL, non-HDL cholesterol, fasting glucose, apolipoprotein B (Apo B), lipoprotein(a), homocysteine, high sensitivity C-reactive protein (hsCRP), fibrinogen, leucocytes count and haemoglobin) were performed in the Clinical Pathology Laboratory of the Central Hospital, with quality accreditation, based on the Agencia de Calidad Sanitaria de Andalucía (ACSA) Model (international version).

A written informed consent was obtained from each participant at the time of enrolment. Approval from the Ethics Committee and from SESARAM was obtained before the start of the study under protocol number 50/2012.

3.2 – Follow-up and Cardiovascular Outcomes

Follow-up was performed from the date of admission until the occurrence of the first registered CV event. We used outpatient visits, telephone interviews, and hospitalisation records to gather follow-up data.

Cardiovascular (CV) events were defined as clinical outcomes resulting from the occurrence or progression of cardiovascular disease. Major or Primary events included nonfatal myocardial infarction, unstable angina, nonfatal stroke, and cardiovascular death, consistent with the conventional composite endpoint of major adverse cardiovascular events (MACE). Secondary events were considered in situations requiring hospitalisation, such as coronary revascularisation procedures (percutaneous coronary intervention or coronary artery bypass grafting), hospitalisation due to heart failure, transient Ischemic Attack (TIA), or peripheral arterial disease (PAD).¹¹ Two cardiologists independently reviewed all prospective and potential outcomes.

Myocardial infarction (MI) was defined as acute myocardial injury detected by abnormal cardiac biomarkers (specifically, a rise and/or fall of cardiac troponin values with at least one value above the 99th percentile upper reference limit) in the presence of evidence of acute myocardial ischemia, indicated by at least one of the following: symptoms of ischemia (such as typical chest pain); new ischemic ECG changes; development of pathological Q waves; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality

consistent with ischemia; or identification of a coronary thrombus by angiography or autopsy.¹²

Unstable angina (UA) is characterized by myocardial ischemia at rest or with minimal exertion, but without evidence of acute myocardial injury — that is, cardiac troponin concentrations remain within the normal range. It typically presents as prolonged (usually >20 minutes) chest pain at rest, new-onset angina of at least CCS class III severity, or crescendo angina (previously stable angina that has become distinctly more frequent, severe, or prolonged). Because high-sensitivity cardiac troponin assays now detect even small amounts of myocardial injury, many cases that were formerly diagnosed as unstable angina are now classified as non-ST-segment elevation myocardial infarction (NSTEMI). Consequently, UA has become increasingly uncommon in current clinical practice.¹³

Coronary vascular revascularization (CR) is established as a percutaneous or surgical intervention aimed at re-establishing adequate perfusion to ischemic tissue by reopening or bypassing an obstructed vessel. Percutaneous coronary intervention (PCI) includes balloon angioplasty with or without stent implantation or atherectomy. Coronary artery bypass grafting (CABG) consists of the creation of a graft to bypass blocked coronary arteries.¹⁴

Ischemic stroke (IS) was defined as a neurological deficit resulting from occlusion of a cerebral artery (accounting for approximately 85% of all stroke cases). Transient ischemic attack (TIA) was defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction, typically resolving within 24 hours.¹⁵

Cardiovascular mortality in this study was defined as death resulting from an atherosclerotic cardiovascular cause, such as acute myocardial infarction (AMI), sudden cardiac death, heart failure or cardiogenic shock, ischemic stroke, cardiovascular procedures or their complications (e.g., during or after PCI or CABG), or peripheral arterial disease leading to death (e.g., due to limb ischemia).¹⁶ For cardiovascular mortality, the criteria used were based on the *International Classification of Diseases, 10th Revision (ICD-10)* codes I21, I25, I25.9, I46.1, and I50. For ischemic stroke mortality, the Portuguese ICD-10 codes I63, I64, and I69 were adopted.

In patients with multiple events, only the time of the first event was used for further analyses.

3.3 - Genetic analysis

DNA was extracted from the peripheral blood leukocytes using a standard salting-out method. A TaqMan allelic discrimination assay for genotyping *GJA4* rs618675 T>C polymorphism was performed on a 7300 Real-Time PCR System using labelled probes and primers pre-established by the supplier (TaqMan, Applied Biosystems). Genotypes were determined without prior knowledge of the individual's clinical data. Quality control of the genotyping technique was maintained by including one non-template control (NTC) on each 96-well plate and a blind duplicate, accounting for 20% of all samples.

3.4 - Statistical analysis

Data are expressed as frequencies and percentages, or as means and standard deviations, except for laboratory analyses, which are presented as medians (minimum-maximum). Gene counts consider allelic and genotypic frequencies. Groups with CV events and non-events are

compared using the Chi-square test. Hardy-Weinberg equilibrium was assessed using observed and expected genotypic frequencies, verified by Pearson's Chi-square test. The independent Student's t test was used to compare means for continuous variables; a nonparametric test (Mann-Whitney) was used when variables were not normally distributed.

For data analysis, we created four genetic models: model 1 - *GJA4* codominant model (CC vs. TT and CT vs. TT); model 2 - *GJA4* recessive model (CC compared with TT+TC); model 3 - *GJA4* dominant model (TC+CC compared with TT) and model 4 - *GJA4* additive model (TT- 0; TC- 1; CC- 2). To report the strength of the association between *GJA4* genetic models and the occurrence of an event, we used bivariate and multivariate logistic regression analysis with the respective odds ratios (OR). We used the Kaplan-Meier estimator for event-free analysis, which estimates the survival function from the start date to the event time. To investigate which variables were significantly and independently associated with CV events, we performed four multivariate Cox regression analyses (adjusted for all significant variables from the bivariate analysis), each with hazard ratios (HRs) and p-values for the respective genetic models. The HR measured the effect size of the predictor variables, which were significantly and independently associated with CV events. Finally, we presented a graph comparing the effect sizes (HRs) and significant variables across all genetic models for the risk of CV events. All analyses were made with SPSS software (version 25.0, SPSS Inc.). At $p < 0.05$, significance was considered.

4 – RESULTS

4.1 - Comparison analysis (Bivariate analysis)

Our study population comprised 73.6% males with a mean age of 52.2 ± 8.3 years. In the analysis window, CV events occurred in 79 (5.6%) patients, shown in Table 1.

Table 1 – Description of the CV events

Events	Total (n=79)
Primary events, n(%)	
CV death	25 (31.6)
MI+UA	15 (19.0)
Stroke+TIA	21 (26.6)
Secondary events, n (%)	
CR	7 (8.9)
HF	6 (7.6)
PAD	5 (6.3)

CV – Cardiovascular; MI – Myocardial infarction; UA – Unstable angina; TIA – Transient ischemic attack; CR – Coronary revascularisation; HF – Heart failure; PAD – Peripheral arterial disease.

A comparison of the patients with CV events versus non-events, concerning their baseline variables (Table 2) showed a higher mean age (56.3 ± 6.9 vs 51.9 ± 8.4 years; $p < 0.0001$) as well as a higher frequency of the usual traditional risk factors, such as male gender (83.5% vs 73.0%; $p = 0.039$), smoking status (38.0% vs 22.7%; $p = 0.002$), hypertension (69.6% vs 49.6%; $p = 0.001$), diabetes (26.6% vs 12.9%; $p = 0.001$), fasting glucose levels (104.0 vs 99.0 mg/dl; $p = 0.015$);

homocysteine levels (12.2 vs 11.6 mmol/L; $p=0.003$), hsCRP (0.47 vs 0.27 mg/dl; $p<0.0001$), and white blood cell count (7.3 vs 6.6 $10^3\mu\text{L}$; $p=0.001$).

Table 2 - Comparison of the baseline characteristics of the population

Variables	Overall (n=1421)	CV events (n=79)	No CV events (n=1342)	P-value
Male gender, n (%)	1046 (73.6)	66 (83.5)	980 (73.0)	0.039
Age, years	52.2 $\pm$ 8.3	56.3 $\pm$ 6.9	51.9 $\pm$ 8.4	<0.0001
Smoking status, n (%)	334 (23.5)	30 (38.0)	304 (22.7)	0.002
Alcohol*, n (%)	185 (13.0)	12 (15.2)	173 (12.9)	0.555
Physical inactivity, n (%)	595 (41.9)	28 (35.4)	567 (42.3)	0.233
BMI $\geq$ 30Kg/m ² , n (%)	405 (28.5)	25 (31.6)	380 (28.3)	0.524
Dyslipidemia, n (%)	991 (69.7)	60 (75.9)	931 (69.4)	0.216
Hypertension, n (%)	720 (50.7)	55 (69.6)	665 (49.6)	0.001
Diabetes, n (%)	194 (13.7)	21 (26.6)	173 (12.9)	0.001
Fasting glucose, mg/dl	99.0 (57.0-364.0)	104.0 (80.0-311.0)	99.0 (57.0-364.0)	0.015
Non-HDL, mg/dl	154.0 (43.0-324.0)	148.0 (43.0-287.0)	154.0 (54.0-324.0)	0.464
Apo B, mg/dl	92.3 (3.4-212.7)	92.4 (4.9-185.1)	92.2 (3.4-212.7)	0.578
Lipoprotein (a), mg/dl	13.4 (0.2-236.0)	14.6 (1.5-112.0)	13.3 (0.2-236.0)	0.646
Homocysteine, mmol/L	11.7 (2.9-109.9)	12.2 (6.3-24.3)	11.6 (2.9-109.9)	0.003
hs-CRP, mg/dl	0.27 (0.01-64.5)	0.47 (0.02-35.9)	0.27 (0.01-64.5)	<0.0001
Fibrinogen, mg/dl	373.0 (127.0-705.0)	381.0 (127.0-582.0)	373.0 (137.0-705.0)	0.351
White blood cell count, 10 ³ μL	6.6 (2.1-19.7)	7.3 (3.8-19.7)	6.6 (2.1-17.5)	0.001
Haemoglobin, g/dl	14.7 (8.2-18.1)	14.7 (11.1-17.8)	14.7 (8.2-18.1)	0.355

CV - Cardiovascular; * $>300\text{gr/week}$; BMI – Body mass index; HDL – High-density lipoprotein; Apo B – Apolipoprotein B; hsCRP – High sensitivity C reactive protein; Statistically significant for $p<0.05$.

4.2- Strength of the association (OR) between genetic polymorphisms and CV events

According to the Hardy-Weinberg equilibrium, the genotype distribution between the CV events group ($\chi^2=0.295$) and the non-event group ($\chi^2=0.011$) was not significantly different.

The frequencies of the wild TT, heterozygous TC, and mutant CC genotypes of the *GJA4* rs618675 T>C were, respectively, 50.6%, 39.2% and 10.1% in the CV events group and 66.2%, 30.4% and 3.4% in the non-events group ($p=0.001$).

In bivariate analysis, there are also significant differences in genotypes between the two studied groups, with ORs of 1.69 ($p=0.032$) for the heterozygous genotype and 3.86 ($p=0.0005$) for the mutant CC genotype (Table 3).

When we used multivariate logistic regression, adjusted for all co-variables statistically significant in bivariate analysis, the significance remained at OR=1.65 ($p=0.049$) for the TC genotype and OR=3.90 ($p=0.002$) for the CC genotype. For the other genetic models, the adjusted ORs were 3.24 ($p=0.005$) for the recessive model, 1.88 ($p=0.008$) for the dominant model, and 1.83 ($p=0.001$) for the additive model (Table 3).

Table 3 - Association between *GJA4* rs618675 T>C and CV events occurrence (Bivariate and Multivariate logistic regression)

rs618675 Genetic model		CV events (n=79)	No CV events (n=1342)	OR* (95% CI)	P-value	Adjusted OR** (95%CI)	P-value
Model 1 (Codominant)	TT	40 (50.6)	888 (66.2)	Reference		Reference	
	TC	31 (39.2)	408 (30.4)	1.69 (1.04-2.74)	0.032	1.65 (1.00-2.72)	0.049
	CC	8 (10.1)	46 (3.4)	3.86 (1.71-8.7)	0.0005	3.90 (1.67-9.08)	0.002
Model 2	Recessive			3.18 (1.44-6.98)	0.002	3.24 (1.43-7.36)	0.005
Model 3	Dominant			1.91 (1.21-3.01)	0.005	1.88 (1.18-3.01)	0.008
Model 4	Additive			1.85 (1.30-2.64)	0.0006	1.83 (1.27-2.65)	0.001

*Bivariate analysis.

**Adjusted multivariate analysis (Covariates: sex, age, hypertension, diabetes, smoking status, homocysteine, hs-CRP, leucocytes).

4.3 - Survival analysis

4.3.1 - Kaplan-Meier estimate analysis

We used the Kaplan-Meier method to compare the wild (TT), heterozygous (TC), and mutant homozygous (CC) genotypes to estimate subjects' probability of remaining event-free over time.

The CC genotype was associated with worse prognosis throughout the follow-up period ($p=0.005$). Specifically, at 16 years of follow-up, CC showed a lower event-free rate of 64.8% compared with wild-type (87.6%) and heterozygous (77.3%) (Figure 1).




Figure 1 - Kaplan-Meier survival analysis for CV events by GJA4 genotypes.

The number of patients at risk are indicated for each time point during follow-up.

4.3.2 - Multivariate Cox regression analysis

Considering the time to the first event, Cox regression analysis estimates the survival function for all *GJA4* genetic models, adjusting for significant variables (gender, age, diabetes, hypertension, smoking status, homocysteine, hs-CRP, and white blood cell count). We considered model 1 (codominant) the best for comparison as it presented the strongest association (HR) with the onset of CV events.

Results show that, in this analysis, the risk CC genotype presented an adjusted HR of 2.81 ($p=0.008$) and the TC heterozygous had an HR of 1.57 ($p=0.064$), together with the male gender (HR=2.07; $p=0.020$), age (HR=1.06; $p=0.001$), smoking status (HR=1.88; $p=0.010$), hypertension (HR=1.93; $p=0.014$), and white blood cell count (HR=1.17; $p=0.003$) (Table 4).

Subsequently, we performed three additional Cox regression analyses using the remaining genetic models, each adjusted for its respective confounder variables. We compared the effect sizes (HRs) of all genetic models on the risk of CV events (Figure 2). This graph shows that all genetic models are significant predictors; however, model 1 (CC vs TT) has the largest magnitude of association for predicting CV events.

Table 4 - Cox proportional hazard analysis for assessing the relation between *GJA4* rs618675 T>C and CV events

Variables	B	SE	Wald	df	Hazard ratio	P-value
-----------	---	----	------	----	--------------	---------

					(95% CI)	
Model 1						
TT	---	---	8.444	2	Reference	0.015
TC	0.448	0.241	3.439	1	1.57 (0.98 - 2.51)	0.064
CC	1.032	0.391	6.980	1	2.81 (1.31 - 6.04)	0.008
Male gender	0.728	0.313	5.404	1	2.07 (1.12 - 3.82)	0.020
Age	0.058	0.017	11.241	1	1.06 (1.02 - 1.10)	0.001
Smoking status	0.631	0.244	6.685	1	1.88 (1.17 - 3.04)	0.010
Hypertension	0.656	0.267	6.063	1	1.93 (1.14 - 3.25)	0.014
White blood count	0.155	0.052	8.921	1	1.17 (1.06 - 1.29)	0.003

CV – Cardiovascular; B – Beta coefficient; SE – Standard error; df – degrees of freedom; CI – Confidence interval; Variables excluded from the equation: diabetes; homocysteine; hs-CRP. Statistically significant for $p < 0.05$.




Figure 2 - The effect size of all CV events risk predictors.

Model 1 – *GJA4* codominant model (CC vs TT) ($p=0.008$); Model 2 – *GJA4* recessive model (CC vs TT+TC) ($p=0.021$); Model 3 – *GJA4* dominant model (TC+CC vs TT) ($p=0.016$); Model 4 – *GJA4* additive model (TT - 0; TC - 1; CC - 2) ($p=0.004$). Variables excluded from the equation: diabetes, homocysteine, and hs-CRP. Statistically significant at $p < 0.05$.

5- Discussion

Coronary artery disease (CAD) is often clinically silent and may progress insidiously over many years before the onset of symptoms. Individuals with subclinical atherosclerosis frequently remain undiagnosed and may appear healthy until the occurrence of a major adverse cardiovascular event, including sudden cardiac death. Early identification of these high-risk individuals provides an opportunity for timely intervention aimed at preventing severe outcomes. Achieving more accurate risk stratification remains a major clinical challenge but could substantially reduce the incidence of myocardial infarction and cardiovascular mortality.¹⁷

Although cardiovascular disease (CVD) has a strong environmental component, a genetic predisposition also contributes significantly to its development. Genetic analysis can complement traditional risk assessment by identifying inherited susceptibility before clinical manifestations.¹⁸ Advances in sequencing technologies have markedly reduced costs, making such analyses more accessible. Incorporating genetic data into conventional risk models—alongside factors such as age, cholesterol, and blood pressure—can improve risk stratification, especially in asymptomatic individuals with subclinical atherosclerosis.¹⁹

As previously described, the *GJA4* gene encodes connexin 37 (Cx37), a gap junction protein essential for intercellular communication in various tissues, including the heart and vascular endothelium. Cx37 plays a key role in endothelial function by modulating inflammatory responses, platelet adhesion, and thrombus formation. Polymorphisms within *GJA4* have been associated with an increased risk of atherosclerosis and myocardial infarction. Such alterations may impair gap junction-mediated signaling in endothelial cells and platelets, promoting abnormal platelet aggregation and thrombus formation, thereby contributing to the development of coronary artery disease and ischemic stroke.²⁰⁻²¹

Our longitudinal study, with comprehensive follow-up, investigated whether the *GJA4* rs618675 T>C genetic variant is associated with the occurrence of cardiovascular events in an asymptomatic population without known coronary artery disease. Carriers of the CC genotype exhibited an adjusted odds ratio of 3.9, indicating approximately 3.9-fold higher odds (~290% increase) of experiencing cardiovascular events compared with individuals with the TT genotype, after adjustment for other covariates. CC showed a lower event-free rate of 64.8% compared with CT (77.3%) or TT (87.6%) genotypes. Furthermore, the hazard ratio (HR) for cardiovascular event risk was 2.81 for the CC genotype relative to the wild-type TT genotype. These findings suggest that the *GJA4* rs618675 CC genotype was associated with worse prognosis throughout the follow-up period.

The rs618675 variant is a non-coding tagging SNP located within the *GJA4* locus and has been associated with increased atherosclerosis and a higher risk of cardiovascular events in several population-based studies. Although it does not alter the amino acid sequence of connexin 37 (Cx37), its association with cardiovascular outcomes was confirmed in the Framingham Offspring cohort, where CC homozygotes demonstrated a 1.7-fold higher hazard of coronary events compared with TT carriers.⁸⁻⁹ This association is likely driven by linkage disequilibrium with the nearby functional missense variant *GJA4* rs1764391 (C1019T, p.Pro319Ser) or by regulatory effects influencing *GJA4* transcription or expression. However, the Framingham analysis was purely epidemiological and did not explore the functional consequences of rs618675. To date, no experimental evidence has demonstrated a direct regulatory role for

this non-coding variant, although its position suggests a potential influence within a regulatory or enhancer element modulating *GJA4* gene activity.

Our asymptomatic population was recently reclassified by SCORE2, which showed that, under the new scoring system, the low-to-moderate group lost population comprised only 24.7% of the overall sample. In comparison, the high- and very-high-risk categories accounted for 75.2% of the total population with a high probability of CV events.²² Adding the *GJA4* rs617586 variant to SCORE2 could enhance cardiovascular risk prediction by capturing lifelong genetic susceptibility and vascular dysfunction not reflected by traditional factors^{23,24}. This may improve risk discrimination and reclassification, particularly among intermediate-risk individuals, enabling more personalized preventive strategies identifying those who would benefit most from lipid-lowering, anti-inflammatory, or lifestyle interventions. The effect is expected to be stronger when combined with other *GJA4* polymorphisms at the same locus, a polygenic risk score or other markers like coronary calcium scoring.

Several studies^{6-7,25}, using different methodologies, investigated the Cx37 rs1764391 polymorphism C1019T. This proline-to-serine change is very close to *GJA4* rs618675 at the same locus. They speculate that this amino-acid alteration affects the tertiary structure of the protein and, consequently, the regulation of its functionality, particularly concerning myoendothelial gap junction intercellular communication and platelet activation and thrombus function. The structure of the Cx37 protein can be affected or modulated by connexin polymorphisms, which impair the EC barrier and platelet reactivity, influencing the progression of atherosclerosis and CV events. Nevertheless, their findings have not yet been validated.

Understanding the predictors of arterial thrombosis and atherosclerosis development is critical and will aid in developing personalised medication to prevent and treat the complications of atherosclerosis and vascular injury. However, significant effort is needed to create accurate risk-stratification tools based on clinical and traditional factors. However, genetic factors and the genetic and environmental influences on an individual's risk remain essential. With the emergence of advanced techniques for analysing human genetic profiles, researchers have moved away from genetic linkage analysis and a candidate gene approach to genome-wide association studies. They focus on studying glycoproteins, receptors expressed on platelet surfaces, and mutations that significantly impact platelet function. There is considerable interindividual variability in platelet responses to agonists and drugs, and the hyperreactivity phenotype appears to be heritable.²⁶ The use of antiplatelet medications to prevent cardiovascular events in individuals without established atherosclerotic disease should be considered for primary prevention in exceptional cases, such as in people with a genetic predisposition to the formation of thrombi, as this tendency can anticipate fatal occlusive cardiovascular and cerebrovascular pathologies. However, the main challenge for future approaches will be individualised antithrombotic therapy, which involves agents targeting genetic defects to alter platelet function, thereby reducing the risk of bleeding and balancing safety with efficacy.

Strengths and limitations

As far as we know, this is the first study in a Portuguese population to establish a correlation between a specific genetic polymorphism in the *GJA4* gene encoding Connexin37 and cardiovascular events. The original sample is relevant: more than 1400 persons, and the mean

follow-up exceeded seven years. Given that the survey was conducted on at the island's only tertiary hospital, we had few opportunities for loss to follow-up. These results are relevant, demonstrating the importance of this polymorphism in the development of cardiovascular events.

Although the initial sample size was adequate, the number of patients with CV events was low, which reduced the accuracy and reliability of the results. Also, the participants were randomly selected, but we cannot assure they are representative of the entire Portuguese population in terms of gender, age, and geographic origin.

There is a need for multicentre studies with larger sample sizes from different regions and diverse ethnic and social backgrounds to confirm the present results.

Conclusions

Most cardiovascular prevention has focused on lipid and cholesterol-lowering therapies guided by LDL values. Antiplatelet therapy has traditionally been prescribed on the basis of estimated cardiovascular risk, without biomarkers to predict treatment response.

Our study demonstrated that the *GJA4* rs618675 T>C polymorphism, expressed in platelets, is significantly associated with cardiovascular (CV) events in an asymptomatic population. If confirmed in larger cohorts, this easily and inexpensively genotyped variant could serve as a valuable biomarker for primary prevention, particularly among younger individuals with few traditional risk factors but a family history and a strong genetic predisposition for CV events. Further research into the functional modulation of the *GJA4* gene, implicated in vascular inflammation and thrombosis, may offer new opportunities to reduce CV risk and develop novel antithrombotic therapies.

Ethics in publishing

1. Does your research involve experimentation on animals?:

No

2. Does your study include human subjects?:

Yes

If yes; please provide name of the ethical committee approving these experiments.:

Ethics Committee of Funchal Hospital Centre approved the study under protocol number 50/2012.

If yes; please confirm authors compliance with all relevant ethical regulations. :

Yes

If yes; please confirm that written consent has been obtained from all patients. :

Yes

3. Does your study include a clinical trial?:

No

4. Are all data shown in the figures and tables also shown in the text of the Results section and

discussed in the Conclusions?:

Yes

Declarations of interest: none

REFERENCES

1. Pohl U. Connexins are key players in controlling vascular plasticity and function. *Physiol Rev.* 2020;100(2):525–572. <https://doi.org/10.1152/physrev.00010.2019>
2. Dbouk HA, Mroue RM, El-Sabban ME, et al. Connexins: myriad functions extending beyond the assembly of gap junction channels. *Cell Comm and Signalling.* 2009;7:4s.
3. Figueroa XF, Duling BR. Gap Junctions in the Control of Vascular Function. *Antioxidants & Redox Signalling.* 2009;11:2. doi: 10.1089/ars.2008.2117.
4. Wong CW, Christen T, Roth I, et al. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. *Nat Med.* 2006;12(8):950–4. doi: 10.1038/nm1441
5. Brass LF, Stalker TJ. Minding the Gaps - and the Junctions, Too. *Circulation.* 2012;125(20):2414–2416. doi: 10.1161/CIRCULATIONAHA.112.106377.
6. Angelillo-Scherrer A, Fontana P, Burnier L, et al. Connexin 37 Limits Thrombus Propensity by Downregulating Platelet Reactivity. *Circulation.* 2011;124:930–939.
7. Vaiyapuri S, Jones CI, Sasikumar P, et al. Gap Junctions and Connexin Hemichannels Underpin Hemostasis and Thrombosis. *Circulation.* 2012;125:2479–2491. <https://doi.org/10.1161/CIRCULATIONAHA.112.101246>.
8. Larson MG, Atwood LD, Benjamin EJ, et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. *BMC Med Genet.* 2007;8 Suppl 1(Suppl 1):S5. doi: 10.1186/1471-2350-8-S1-S5.
9. Yan Y, Hu Y, North KE, et al. Evaluation of population impact of candidate polymorphisms for coronary heart disease in the Framingham Heart Study Offspring Cohort. *BMC Proc.* 2009;3 Suppl 7(Suppl 7):S118. doi: 10.1186/1753-6561-3-s7-s118.
10. Mendonça MI, Henriques E, Borges S, et al. Genetic information improves the prediction of major adverse cardiovascular events in the GENEMACOR population. *Genet Mol Biol.* 2021;44:e20200448.
11. Bhatta A, Wilkinson C, Sydes M, et al. Defining the need for cardiovascular event definitions. *Eur Heart J Qual Care Clin Outcomes.* 2024;10(2):105–107. doi:10.1093/ehjqcco/qcae008.
12. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). *Eur Heart J.* 2019;40(3):237–269. doi:10.1093/eurheartj/ehy462.
13. Collet JP, Thiele H, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J.* 2023;44(35):3720–3826.
14. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularisation. *Circulation.* 2022;145(3):e4–e17.
15. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke.* 2021;52(7):e364–e467. doi:10.1161/STR.0000000000000375.

16. Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation*. 2018;137(9):961-972. doi:10.1161/CIRCULATIONAHA.117.033502.
17. Shahjehan RD, Sharma S, Bhutta BS. Coronary Artery Disease. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; October 9, 2024.
18. Hajar R. Genetics in Cardiovascular Disease. *Heart Views*. 2020;21(1):55-56. doi:10.4103/HEARTVIEWS.HEARTVIEWS_140_19.
19. Samani NJ, Beeston E, Greengrass C, et al. Polygenic risk score adds to a clinical risk score in predicting cardiovascular disease in a clinical setting. *Eur Heart J*. 2024;45(34):3152-3160. doi: 10.1093/eurheartj/ehae342.
20. Li H, Yu S, Wan R, et al. Polymorphism of the CONNEXIN37 gene is a risk factor for ischemic stroke in the Han Chinese population. *Lipids Health Dis*. 2018;17:72.
21. Leu HB, Chung CM, Chuang SY, et al. Genetic variants in connexin37 are associated with carotid intima-media thickness and the future onset of ischemic stroke. *Atherosclerosis*. 2011;214(1):101.
22. Temtem M, Mendonça MI, Santos M, et al. Validation of the SCORE2 risk prediction algorithm in a Portuguese population: A new model to estimate 10-year cardiovascular disease incidence in Europe. *Rev Port Cardiol*. 2024;43(8):437-444. doi:10.1016/j.repc.2023.10.011.
23. Pereira Santos S, Guedes S, Pesqueira R, Stuart J, Carvalho AM, Correia P, Lourenço Ribeiro I, Teixeira ÂM. Cardiovascular risk assessment using SCORE2 in a population with hypertension - The reality at a primary health care unit. *Rev Port Cardiol*. 2024 Nov;43(11):601-610. doi: 10.1016/j.repc.2024.03.007.
24. Silva C, Mendes JE, Ramos R, Gaspar A, Leal F, Mendes N. Cardiovascular risk assessment in Portugal's primary health care system: SCORE vs. SCORE2. *Rev Port Cardiol*. 2024 Aug;43(8):449-455. doi: 10.1016/j.repc.2023.10.012.
25. Li Z, Smyth S. Connexins Counteract Clotting. *Circulation*. 2011;124:873-875.
26. Galli M, Terracina S, Schiera E, et al. Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital. *J Thromb Thrombolysis*. 2025;58(1):71-83. doi:10.1007/s11239-024-03022-w.

Figure's legends:

Figure 1 - Kaplan-Meier survival analysis for CV events by GJA4 genotypes.

The number of patients at risk are indicated for each time point during follow-up.





Figure 2 - The effect size of all CV events risk predictors.



Model 1 – GJA4 codominant model (CC vs TT) ($p=0.008$); Model 2 – GJA4 recessive model (CC vs TT+TC) ($p=0.021$); Model 3 – GJA4 dominant model (TC+CC vs TT) ($p=0.016$); Model 4 – GJA4 additive model (TT - 0; TC - 1; CC - 2) ($p=0.004$). Variables excluded from the equation: diabetes, homocysteine, and hs-CRP. Statistically significant at $p<0.05$.